Wells Fargo initiated coverage of Revolution Medicines (RVMD) with an Overweight rating and $67 price target The firm believes daraxonrasib’s mechanism of action is “de-risked” in pancreatic ductal adenocarcinoma and second-line non-small cell lung cancer. A positive readout for the RASolute302 trial, expected in 2026, is a high probability, the analyst tells investors in a research note. Wells likes the setup for Revolution shares over the next 12-18 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines’ Innovative RAS(ON) Platform and Strategic Collaborations Drive Buy Rating
- Revolution Medicines’ Earnings Call: Progress Amid Challenges
- Optimistic Outlook for Revolution Medicines Amid Strategic Developments and Pipeline Progress
- Revolution Medicines Advances RAS-Targeted Therapies
- Revolution Medicines reports Q2 EPS ($1.31), consensus ($1.12)